Hypertension in China: the gap between policy and practice

Affiliations

¹ UCL Institute for Global Health, University of London, London, WC1N 1EH, UK; Zhejiang University School of Public Health, Hangzhou, China. Electronic address: t.hesketh@ucl.ac.uk.
² Zhejiang University School of Public Health, Hangzhou, China.

Comment

Therese Hesketh et al. Lancet. 2017.

. 2017 Dec 9;390(10112):2529-2530.

doi: 10.1016/S0140-6736(17)32743-5. Epub 2017 Nov 5.

¹ UCL Institute for Global Health, University of London, London, WC1N 1EH, UK; Zhejiang University School of Public Health, Hangzhou, China. Electronic address: t.hesketh@ucl.ac.uk.
² Zhejiang University School of Public Health, Hangzhou, China.

No abstract available

Comment on

Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project).
Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, Cheng X, Mu L, Zhang H, Liu J, Su M, Zhao H, Spatz ES, Spertus JA, Masoudi FA, Krumholz HM, Jiang L. Lu J, et al. Lancet. 2017 Dec 9;390(10112):2549-2558. doi: 10.1016/S0140-6736(17)32478-9. Epub 2017 Nov 5. Lancet. 2017. PMID: 29102084
Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey.
Su M, Zhang Q, Bai X, Wu C, Li Y, Mossialos E, Mensah GA, Masoudi FA, Lu J, Li X, Salas-Vega S, Zhang A, Lu Y, Nasir K, Krumholz HM, Jiang L. Su M, et al. Lancet. 2017 Dec 9;390(10112):2559-2568. doi: 10.1016/S0140-6736(17)32476-5. Epub 2017 Nov 5. Lancet. 2017. PMID: 29102087